RESUMO
Antibody based products are not widely available to address multiple global health challenges due to high costs, limited manufacturing capacity, and long manufacturing lead times. Nicotiana-based manufacturing of antibody products may now begin to address these challenges as a result of revolutionary advances in transient expression and altered glycosylation pathways. This review provides examples of emerging antibody-based products (mucosal and systemic) that could be competitive and commercially viable when the attributes of Nicotiana-based manufacturing (large scale, versatile, rapid, low cost) are utilized.
Assuntos
Anticorpos Monoclonais/biossíntese , Formação de Anticorpos , Nicotiana/metabolismo , Doença de Alzheimer/imunologia , Peptídeos beta-Amiloides/imunologia , Animais , Doenças Autoimunes/tratamento farmacológico , Produtos Biológicos/biossíntese , Guerra Biológica/prevenção & controle , Comércio , Doenças Transmissíveis Emergentes/imunologia , Doenças Transmissíveis Emergentes/prevenção & controle , Anticoncepção/métodos , Glicosilação , Humanos , Imunoglobulina G/uso terapêutico , Imunoglobulinas Intravenosas/uso terapêutico , Inflamação/tratamento farmacológico , Camundongos , Polissacarídeos/biossíntese , Gravidez não Planejada , Infecções por Vírus Respiratório Sincicial/economia , Infecções por Vírus Respiratório Sincicial/prevenção & controle , Vírus Sinciciais Respiratórios/imunologia , Infecções Sexualmente Transmissíveis/prevenção & controle , Nicotiana/imunologia , Vacinas de Subunidades Antigênicas/biossínteseRESUMO
Mathematical models provide a powerful tool for investigating the dynamics and control of infectious diseases, but quantifying the underlying epidemic structure can be challenging especially for new and under-studied diseases. Variations of standard SIR, SIRS, and SEIR epidemiological models are considered to determine the sensitivity of these models to various parameter values that may not be fully known when the models are used to investigate emerging diseases. Optimal control theory is applied to suggest the most effective mitigation strategy to minimize the number of individuals who become infected in the course of an infection while efficiently balancing vaccination and treatment applied to the models with various cost scenarios. The optimal control simulations suggest that regardless of the particular epidemiological structure and of the comparative cost of mitigation strategies, vaccination, if available, would be a crucial piece of any intervention plan.